Cell proliferation and vascularization were studied in I0 human breast carcinomas by an immunoenzyme technique. The monoclonal antibody (MAb) Ki-67 was used as a marker for proliferating cells and a polyclonal antibody directed against human von-Willebrand factor to identify blood vessels. The propo
Phospholipid metabolites, prognosis and proliferation in human breast carcinoma
β Scribed by T. A. D. Smith; C. Bush; C. Jameson; J. C. Titley; M. O. Leach; D. E. V. Wilman; V. R. McCready
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 604 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0952-3480
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The content of the phospholipid metabolites, phosphocholine, phosphoethanolamine, glycerophosphorylcholine and glycerophosphorylethanolamine was measured in chemical extracts from 46 human breast carcinoma using ^31^P NMR spectroscopy. Some patients had received therapy prior to tumour resection. The data were therefore stratified into two groups: (i) all tumours; and (ii) untreated tumours. Three indices of tumour proliferation i.e., mitotic index, Ki67 and Sβphase fraction were determined on tissue from the same tumours and were found not to correlate with the content of any of these metabolites. In addition oestrogenβreceptor status and density, tumour grade and DNA ploidy were obtained on some tumours. The phosphocholine content was higher in high grade tumours when compared with low grade tumours. There was no apparent relationship between DNA ploidy and the content of any of these metabolites. Glycerophosphorylcholine content of oestrogenβreceptor positive tumours correlated with receptor density. However, there was no significant difference between receptor positive and negative tumours in the content of any of the phospholipid metabolites measured.
π SIMILAR VOLUMES
## Abstract DNA content was estimated in 705 breast carcinomas from patients with stage I or stage II disease undergoing mastectomy, to investigate whether it would predict the clinical course of the disease. The patients were then followed for up to 84 months during which time 166 of them develope
In the present study the prognostic value of tumor S-phase fraction was evaluated in 69 patients with renal-cell carcinoma. The proportion of S-phase cells was calculated from DNA histograms by flow cytometry in multiple samples from each tumor. The mean tumor S-phase percentage varied between 1.0 a
We have used immunohistochemical staining to assess the expression of cyclin D I in formalin-fixed sections of 345 breast carcinomas, dating back 20 years. Clinical follow-up data were available on all patients. Approximately 50% of the tumours showed excessive nuclear staining for cyclin DI as comp
those dying from recurrent disease within this period. .